Journal: Bioactive Materials

Article Title: Mesenchymal stromal cells-loaded 3D radially aligned composite scaffold with potentiated paracrine signaling for sequential bone regeneration

doi: 10.1016/j.bioactmat.2026.02.059

Figure Lengend Snippet: Temporal analysis of the BMSC paracrine profile on different scaffolds. (A) Confocal microscopy images from Live/Dead fluorescence staining of BMSCs encapsulated within the PCL/HAp-GelMA/BMSCs scaffold after 1, 3, 5, and 14 d of 3D culture (live cells, green; dead cells, red). (B) The concentrations of key paracrine factors (TGF-β, PGE2, VEGF, HGF, and BMP-2) from BMSCs cultured in different scaffolds, quantified from culture supernatants at day 3 and day 7. (C) Corresponding relative mRNA expression levels of TGFB1, PTGS2, VEGFA, HGF, and BMP-2 in BMSCs at day 3 and day 7, as determined by qPCR analysis. Data are presented as mean ± SD (n = 3) *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns: not significant.

Article Snippet: ELISA kits for PGE2 (Cat. No. E-EL-0034), TGF-β (Cat. No. E-EL-0162), VEGF (Cat. No. E-EL-R2603), and HGF (Cat. No. E-EL-R0496) were purchased from Elabscience (Wuhan, China).

Techniques: Confocal Microscopy, Fluorescence, Staining, Cell Culture, Expressing

Journal: Frontiers in Pharmacology

Article Title: Ranitidine attenuates myocardial fibrosis by suppressing histamine/H2 receptor signaling and FAK/Src activation

doi: 10.3389/fphar.2026.1874499

Figure Lengend Snippet: Ranitidine inhibits TGF-β1-induced total collagen accumulation in NIH/3T3 fibroblasts. Total collagen content was measured by Sirius red assay. Data are presented as mean ± SD from three independent experiments. *p < 0.05.

Article Snippet: Key reagents included ranitidine (Macklin, R838252, purity >98%), valsartan (Macklin, V844023, purity >95%), and TGF-β1 (MedChemExpress, HY-P7117, purity >95%).

Techniques:

Journal: Frontiers in Pharmacology

Article Title: Ranitidine attenuates myocardial fibrosis by suppressing histamine/H2 receptor signaling and FAK/Src activation

doi: 10.3389/fphar.2026.1874499

Figure Lengend Snippet: Ranitidine inhibits the expression of fibrosis-related proteins and reduces FAK/Src activation in TGF-β1-stimulated fibroblasts. (A) Representative Western blot images of p-FAK, FAK, p-Src, Src, α-SMA, Collagen I, Collagen III, and GAPDH in fibroblasts treated with TGF-β1 (15 ng/mL) with or without ranitidine (RN, 0.1, 1, and 10 μM). (B–D) Quantification of α-SMA, Collagen I, and Collagen III protein expression. (E,F) Quantification of p-FAK and p-Src protein expression. Data are presented as mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Article Snippet: Key reagents included ranitidine (Macklin, R838252, purity >98%), valsartan (Macklin, V844023, purity >95%), and TGF-β1 (MedChemExpress, HY-P7117, purity >95%).

Techniques: Expressing, Activation Assay, Western Blot

Journal: Frontiers in Pharmacology

Article Title: Ranitidine attenuates myocardial fibrosis by suppressing histamine/H2 receptor signaling and FAK/Src activation

doi: 10.3389/fphar.2026.1874499

Figure Lengend Snippet: Ranitidine reduces the mRNA expression of fibrosis-related markers in TGF-β1-stimulated fibroblasts. (A–C) Relative mRNA expression levels of α-SMA, Collagen I, and Collagen III in fibroblasts treated with TGF-β1 (15 ng/mL) with or without ranitidine (RN, 0.1, 1, and 10 μM). Data are presented as mean ± SD from three independent experiments. ***p < 0.001.

Article Snippet: Key reagents included ranitidine (Macklin, R838252, purity >98%), valsartan (Macklin, V844023, purity >95%), and TGF-β1 (MedChemExpress, HY-P7117, purity >95%).

Techniques: Expressing